AI + ribociclib (HR+/HER2- metastatic 1L; OS-validated)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-LETROZOLE` `DRUG-RIBOCICLIB`

ID	`REG-AI-RIBOCICLIB`
Type	Regimen
Status	pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-BREAST-METASTATIC-2024` `SRC-NCCN-BREAST-2025`

Notes

MONALEESA-2/3/7: OS benefit in metastatic HR+/HER2- 1L+ premenopausal + postmenopausal subgroups. NATALEE: 3-year adjuvant role established for high-risk N+ HR+/HER2- early breast (separate Indication needed).

Used By

Handbook Chapters

HB-BREAST-HR-POS-HER2-NEG-1L - HR+/HER2- metastatic breast cancer: first-line reasoning

Indication

IND-BREAST-HR-POS-EARLY-ADJ-RIBOCICLIB - IND-BREAST-HR-POS-EARLY-ADJ-RIBOCICLIB
IND-BREAST-HR-POS-MET-1L-CDKI - IND-BREAST-HR-POS-MET-1L-CDKI

Regimen

REG-RIBOCICLIB-AI-ADJUVANT - Ribociclib adjuvant + AI (HR+/HER2- early breast cancer; NATALEE)